Anzeige
Mehr »
Login
Dienstag, 23.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Breaking News: InnoCan startet in eine neue Ära – FDA Zulassung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
4 Leser
Artikel bewerten:
(0)

Varian Medical Systems' ARIA Oncology Information System Certified for Use to Demonstrate Stage 1 and 2 "Meaningful Use" of an Electronic Health Record

PALO ALTO, Calif., July 22, 2014 /PRNewswire/ -- Varian Medical Systems (NYSE:VAR) today announced that its ARIA® oncology information system has been certified for use to demonstrate Stage 1 and 2 "meaningful use" of an electronic health record (EHR). Clinicians will soon be able to use the system to qualify for funding under the federal government's program to improve clinical care by promoting the adoption and effective use of EHRs at healthcare institutions.

The ARIA system for both medical and radiation oncology were tested and certified as a Complete Ambulatory EHR under the Drummond Group's Electronic Health Records Office of the National Coordinator Authorized Certification Body (ONC-ACB) program. The Drummond Group's ONC-ACB certification program certifies that EHRs meet the meaningful use criteria for eligible providers.

Varian's ARIA software system is a comprehensive electronic medical record and image management system that aggregates patient data into an organized, oncology-specific medical chart with functional components for managing clinical, administrative and financial operations for medical, radiation and surgical oncology. The certification means that the software complies with criteria adopted by the Secretary of the U.S. Department of Health and Human Services for electronic healthcare records. Eligible providers can now qualify to receive federal stimulus monies upon demonstrating meaningful use of Varian's certified software system for establishing and maintaining electronic healthcare records.

"Enhancing the ARIA system to qualify for this certification was a significant achievement and the result of close collaboration with members of the clinical oncology community," said Sukhveer Singh, vice president of Varian's Oncology Continuum Solutions group, a dedicated team working to deliver software solutions that enable more patient-centered and outcome-driven care along the care continuum. "While this certification is relevant only to clinical sites in the U.S., we are confident that many of the interoperability and quality measures that were added to ARIA will be of great use to the wider global community of clinicians."

The ARIA oncology information system (version 11 MR5), coupled with the Equicare Health Solutions Active Patient Portal (version 4.2) for providing patients with secure web-based access to important portions of their medical records, were certified together to meet the federal requirements for Complete Ambulatory EHR.

Additional Information

These Complete EHRs are 2014 Edition compliant and have been certified by an ONC-ACB in accordance with the applicable certification criteria adopted by the Secretary of the U.S. Department of Health and Human Services. This certification does not represent an endorsement by the U.S. Department of Health and Human Services or guarantee the receipt of incentive payments. ARIA version 11 MR5 was certified on June 26, 2014. Certified ID numbers are 06262014-2528-1 (for radiation oncology) and 06262014-2529-1 (for medical oncology). The modules tested were 170.314(a)(1-15); 170.314(b)(1-5, 7); 170.314(c)(1-3);170.314(d)(1-8); 170.314(e)(1-3); 170.314(f)(1-3); 170.314(g)(2-4). Clinical Quality Measures certified: CMS002v3; CMS050v2; CMS068v3; CMS069v2; CMS124v2; CMS125v2; CMS129v3; CMS130v2; CMS138v2; CMS139v2; CMS140v2; CMS141v3; CMS154v2; CMS156v2; CMS157v2; and CMS165v2. Additional software used: Data Motion, Equicare, Microsoft Word.

Price Transparency

These certified products generally involve one-time license fees plus some ongoing costs:

  • ARIA Disease Management, a one-time initial license fee and ongoing Software Support Agreement (SSA) fees.
  • Equicare Health Solutions Active Patient Portal, a one-time initial license fee and ongoing SSA fees.
  • ePrescribing, a one-time initial license fee and ongoing SSA fees.
  • Interfaces: In and Outbound Laboratory, Immunization, Syndromic Health, a one-time initial license fee/interface and ongoing SSA fees.
  • DIRECT, a one-time initial license fee and ongoing service fees.

About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes, digital detectors, and image processing software and workstations for X-ray imaging in medical, scientific, and industrial applications and also supplies high-energy X-ray devices for cargo screening and non-destructive testing applications. Varian Medical Systems employs approximately 6,500 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com or follow us on Twitter.

FOR INFORMATION CONTACT:
Spencer Sias, 650-424-5782
spencer.sias@varian.com

SOURCE Varian Medical Systems

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.